GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » Beneish M-Score

KNSA (Kiniksa Pharmaceuticals International) Beneish M-Score : -3.17 (As of Oct. 08, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals International Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.17 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Kiniksa Pharmaceuticals International's Beneish M-Score or its related term are showing as below:

KNSA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.17   Med: 1.92   Max: 7.02
Current: -3.17

During the past 8 years, the highest Beneish M-Score of Kiniksa Pharmaceuticals International was 7.02. The lowest was -3.17. And the median was 1.92.


Kiniksa Pharmaceuticals International Beneish M-Score Historical Data

The historical data trend for Kiniksa Pharmaceuticals International's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals International Beneish M-Score Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - - 4.75 -2.51

Kiniksa Pharmaceuticals International Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 -2.90 -2.51 -1.89 -3.17

Competitive Comparison of Kiniksa Pharmaceuticals International's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiniksa Pharmaceuticals International's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Beneish M-Score falls into.



Kiniksa Pharmaceuticals International Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Kiniksa Pharmaceuticals International for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6875+0.528 * 1.087+0.404 * 0.913+0.892 * 1.2069+0.115 * 0.9773
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1459+4.679 * -0.09251-0.327 * 1.4226
=-3.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun24) TTM:Last Year (Jun23) TTM:
Total Receivables was $20.5 Mil.
Revenue was 108.631 + 79.858 + 83.395 + 67.046 = $338.9 Mil.
Gross Profit was 66.295 + 48.474 + 113.396 + 40.647 = $268.8 Mil.
Total Current Assets was $301.0 Mil.
Total Assets was $542.4 Mil.
Property, Plant and Equipment(Net PPE) was $12.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.0 Mil.
Selling, General, & Admin. Expense(SGA) was $152.3 Mil.
Total Current Liabilities was $84.3 Mil.
Long-Term Debt & Capital Lease Obligation was $9.3 Mil.
Net Income was -3.908 + -17.704 + 25.237 + -13.855 = $-10.2 Mil.
Non Operating Income was 2.421 + 2.266 + 2.369 + 2.428 = $9.5 Mil.
Cash Flow from Operations was 5.168 + 3.987 + 4.325 + 16.986 = $30.5 Mil.
Total Receivables was $24.7 Mil.
Revenue was 71.473 + 48.345 + 61.884 + 99.135 = $280.8 Mil.
Gross Profit was 49.788 + 33.021 + 71.723 + 87.575 = $242.1 Mil.
Total Current Assets was $246.0 Mil.
Total Assets was $484.3 Mil.
Property, Plant and Equipment(Net PPE) was $14.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.3 Mil.
Selling, General, & Admin. Expense(SGA) was $110.1 Mil.
Total Current Liabilities was $47.5 Mil.
Long-Term Debt & Capital Lease Obligation was $11.3 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(20.451 / 338.93) / (24.65 / 280.837)
=0.06034 / 0.087773
=0.6875

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(242.107 / 280.837) / (268.812 / 338.93)
=0.862091 / 0.79312
=1.087

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (301.021 + 12.404) / 542.428) / (1 - (246.04 + 14.327) / 484.332)
=0.422181 / 0.46242
=0.913

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=338.93 / 280.837
=1.2069

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.293 / (2.293 + 14.327)) / (2.039 / (2.039 + 12.404))
=0.137966 / 0.141176
=0.9773

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(152.284 / 338.93) / (110.112 / 280.837)
=0.449308 / 0.392085
=1.1459

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((9.317 + 84.291) / 542.428) / ((11.283 + 47.472) / 484.332)
=0.172572 / 0.121311
=1.4226

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-10.23 - 9.484 - 30.466) / 542.428
=-0.09251

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Kiniksa Pharmaceuticals International has a M-score of -3.17 suggests that the company is unlikely to be a manipulator.


Kiniksa Pharmaceuticals International Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiniksa Pharmaceuticals International Business Description

Traded in Other Exchanges
N/A
Address
2 Church Street, Clarendon House, Hamilton, BMU, HM11
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Executives
Eben Tessari officer: Chief Business Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat officer: Group VP & Rilonacept GM C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
John Paolini officer: Chief Medical Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Mark Ragosa officer: Interim CFO C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421
Sanj K Patel director, 10 percent owner, officer: Chairman & CEO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Michael R Megna officer: Chief Accounting Officer 1050 HINGHAM STREET, ROCKLAND MA 02370
Barry D Quart director C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker director BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Arian Pano officer: Chief Clinical Dev. Officer C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham 10 percent owner, officer: Chief Legal Officer C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
G Bradley Cole director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063